logo
Share SHARE
FONT-SIZE Plus   Neg

Roche, PTC Sign Deal To Advance Treatment For Spinal Muscular Atrophy

Roche Holding AG (RHHBY.PK), PTC Therapeutics, Inc. and the SMA Foundation, announced a licensing agreement for PTC's Spinal Muscular Atrophy, or SMA, programme. SMA is a genetic neuromuscular disorder that causes muscle weakness.

As per the terms of the agreement, Roche gains an exclusive worldwide license to PTC's SMA programme, which includes three compounds currently in preclinical development, as well as potential back-up compounds. PTC receives $30 million as an upfront payment, up to $460 million upon successful completion of certain development and commercialization milestones and up to double-digit royalties on commercial sales. PTC noted that development will be overseen by a joint steering committee comprised of members from Roche, PTC and the SMA Foundation.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Fiat Chrysler Automobiles's US will focus on Jeep SUVs and Ram Pickups and plans to stop producing small passenger cars from early next year. The plan to stop Dart and Chrysler 200 production will be effective by first quarter of 2017. The new plans are expected to increase profit margins, as SUVs... Royal Bank of Canada got the highest ranking in overall customer satisfaction among the five biggest Canadian banks, according to the results of an annual survey released Thursday. The lender toppled Toronto-Dominion Bank, which had held the top spot for the past ten years. Ford Motor Co.(F) reported a profit for the second-quarter that declined 8.8 percent from last year, while total revenue increased about 6 percent. The company now sees risks challenging achieving 2016 guidance.
comments powered by Disqus
Follow RTT